Haemostatic abnormalities in liver disease: Could some haemostatic tests be useful as liver function tests?

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 5, 2005, Pages 329-335

  Al Ghumlas, Abeer K ^a   Abdel Gader, Abdel Galil M ^a   Al Faleh, Faleh Z ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Dysfibrinogenaemia; Haemostasis; Liver disease; Protein C; Protein S; Reptilase time

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; BATROXOBIN; BLOOD CLOTTING FACTOR; FIBRINOLYTIC FACTOR; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEPATITIS; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; COLORIMETRY; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOSTASIS; HEPATITIS B; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; REPTILASE TIME; THROMBIN TIME; TURBIDIMETRY;

EID: 22444434861     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000174080.54871.6b     Document Type: Article

References (51)

1. Johnson PJ, McFarlane IG. The laboratory investigation of liver disease. London: Bailliere Tindall, W.B. Saunders; 1989.
2. O'Grady JG, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of fulminant hepatic failure. Semin Liver Dis 1986; 6:159-163.
3. Mammen EF. Coagulation abnormalities in liver disease. Haemotol Oncol Clin North Am 1992; 6:1247-1257.
4. Kelly DA, Summerfield JA. Hemostasis in liver disease. Semin Liver Dis 1987; 7:182-191.
5. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994; 78:545-554.
6. Sato S, Murakami A, Yoshida T, Kashiwabara T, Suzuki K, Kaito I. Usefulness of antithrombin III and alpha 2-plasmin inhibitor in early differentiation of fulminant hepatitis and severe form of acute hepatitis. Gastroenterol Jpn 1983; 18:128-136.
7. Ktoczko J, Mian M, Wojtukiewicz MZ, Babiuch L, Bielawiec M, Galar M. Plasma protein C as a marker of hepatocellular damage in alcoholic liver disease. Haemostasis 1992; 22:340-344.
8. Vukovich Th, Teufelsbauer H, Fritzer M, Kreuzer S, Knoflach P. Hemostasis activation in patients with liver cirrhosis. Thromb Res 1995; 77:271-278.
9. Kato S, Kawasaki H. Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma. Nippon Shokakibyo Gakkai Zasshi 1995; 92:1143-1148.
10. De Caterina M, Tarantino G, Farina C, Arena A, di Maro G, Esposito P, Scopacasa F. Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S. Haemostasis 1993; 23:229-235.
11. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96:1581-1586.
12. Ellis BC, Stransky AA. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Med 1961; 58:477-488.
13. Poller L. Coagulation abnormalities in liver disease. In: Poller L (editor): Recent advances in blood coagulation. Edinburgh: Churchill Livingstone; 1977, pp. 267-292.
14. Takahasi H, Tatewaki W, Wada K, Niwano H, Shibata A. Fibrinolysis and fibrinogenolysis in liver disease. Am J Hematol 1990; 34:241-245.
15. Al-Mofleh IA, Al Faleh FZ, Allam A, Gader AMA. Blood coagulation changes in liver disease. Trop Geogr Med 1989; 41:247-253.
16. Violi F, Ferro D, Basili S, Cimminiello C, Saliola M, Vezza E, Cordova C, the CALC Group. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology 1995; 22:96-100.
17. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F, the CALC Group. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993; 17:78-83.
18. Ho CH, Hou MC, Lin HC, Lee FY, Wu JC, Lee SD. Haemostatic changes in patients with liver cirrhosis. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62:376-382.
19. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96:1581-1586.
20. Scheig R. Evaluation of tests used to screen patients with liver disorders. Gastroenterology 1996; 23:551-560.
21. Fiore L, Levine J, Deykin D. Alterations of hemostasis in patients with liver disease. In: Zakim DZ, Boyer TD (editors): Hepatology: a Textbook of liver disease, 2nd edition, Saunders, Philadelphia, USA volume 1. 1990, pp. 546-571.
22. Lane DA, Scully MF, Thomas P, Kakkar VV, Woolf IL, Williams R. Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol 1977; 35:301-308.
23. Dettori AG, Ponari O, Civardi E, Megha A, Pini M, Poti R. Impaired fibrin formation in advanced cirrhosis. Haemostasis 1977; 6:137-148.
24. Barr RD, Ouna N, Simpson JG, Bagshawe AF. Dysfibrinogenaemia and primary hepto-cellular carcinoma. Q J Med 1976; 45:647-659.
25. Paramo JA, Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost 1993; 19:184-190.
26. Weinstein MJ, Deykin D. Quantitative abnormalities of an Aα chain molecular weight form in the fibrinogen of cirrhotic patients. Br J Haematol 1978; 40:617-730.
27. Lurie B, Creter D. Coagulation studies for severe liver disease detection in a gastroenterologic department. Digestion 1981; 21:244-247.
28. Ragni MV, Lewis JH, Spero JA, Hasiba U. Bleeding and coagulation abnormalities in alcoholic cirrhotic liver disease. Alcohol Clin Exp Res 1982; 6:267-274.
29. Szczepanski M, Habior A, Azczepanik A, Soszka A, Grel K. Thrombin clotting time and fibrin polymerization in liver cirrhosis. Mater Med Pol 1994; 26:87-90.
30. Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94:2801-2803.
31. Van Cott EM, Smith EY, Galanakis DK. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time. Am J Clin Pathol 2002; 118:263-268.
32. Akiyama K, Nakamura K, Makino I, Takeda Y, Kubota K, Tazawa S, et al. Antithrombin III producing hepatocellular carcinoma. Thromb Res 1993; 72:193-201.
33. Boks AL, Brommer EJP, Schalm SW, van Vliet HHDM. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6:79-86.
34. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992; 15: 672-676.
35. Ratnoff OD. The haemostatic defects of liver disease. In: Ogston D, Bennett B (editors): Haemostasis: biochemistry, physiology and pathology. London: John Wiley and Sons; 1977, pp. 446-466.
36. Raya-Sanchez JM, Gonzales-Reimers E, Rodriguez-Martin JM, Santolaria-Fernandez F, Molina-Perez M, Rodriguez-Moreno F, Martinez-Riera A. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15: 19-23.
37. Bell H, Odegaard OR, Andersson T, Raknerud N. Protein C in patients with alcoholic cirrhosis and other liver diseases. J Hepatol 1992; 14:163-167.
38. Rodzynek JJ, Urbain D, Leautaud P, Wettendorff P, Delcourt A. Antithrombin III, plasminogen and alpha2 antiplasmin in jaundice. Clinical usefulness and prognostic significance. Gut 1984; 25:1050-1056.
39. Park CJ, Cho HI, Kim SI. A study on changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma. J Korean Med Sci 1991; 6:1-6.
40. Dumontier I, Alhenc-Gelas M, Chatellier G, Brenet P, Aiach M, Petite JP. Changes in levels of blood coagulation inhibitors in cirrhosis. Prospective study in 33 patients. Gastroenterol Clin Biol 1992; 16:120-125.
41. Romero Gomez M, Suarez-Garcia E, Lopez-Lacornba D, Marchante I, Grande L, Castro-Fernandez M. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2000; 31:237-240.
42. Langley PG, Williams R. Physiological inhibitors of coagulation in fulminant hepatic failure. Blood Coagul Fibrinolysis 1992; 3:243-247.
43. Castelino DJ, Salem HH. Natural anticoagulants and the liver. J Gastroenterol Hepatol 1997; 12:77-83.
44. Brudasca I, Cucuianu M, Stancu A, Colhon DM. Plasma protein S-antigen (PS: Ag) in selected disease states. Rom J Intern Med 1994; 32:29-35.
45. Wolf M, Boyer-Neumann C, Peynaud-Debayle E, Marfaing-Koka A, Amiral J, Meyer D. Clinical applications of a direct assay of free protein S antigen using monoclonal antibodies. A study of 59 cases. Blood Coagul Fibrinolysis 1994; 5:187-192.
46. Tamei H, Hoshino T, Yoshida S, Hayashi T, Iwata K, Suzuki K. One step sandwich enzyme immunoassays for human C4b-binding protein (C4BP) and protein S-C4BP complex using monoclonal antibodies. Clin Chim Acta 1995; 243:115-125.
47. Salem HH. The natural anticoagulants. Clin Haematol 1996; 15:371-391.
48. Philips DJ, Novinger MS, Evatt BL, Hooper WC. TNF-alpha suppresses IL-1 alpha and IL-6 upregulation of C4b-binding protein in HepG-2 hepatoma cells. Thromb Res 1996; 81:307-314.
49. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37:772-777.
50. Pernambuco JRB, Langley PG, Hughes RD, Izumi S, Williams R. Fibrinolytic abnormalities following liver transplantation in patients with fulminant hepatic failure. Eur J Gastroenterol Hepatol 1995; 7:155-159.
51. Garello E, Battista S, Bar F, Niro GA, Cappello N, Rizzetto M, Molino G. Evaluation of hepatic function in liver cirrhosis. Dig Dis Sci 1999; 44: 782-788.